Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.17, read 2026-11-02
Ethical does not pass the values gate
Price56.60 USD
Fair value63.32
Ethical score70.0/100
Value readUndervaluedas of 4 Nov 2026
Our investment reviews on this name
2026-10-11Read Markup41.18+37.4% to today ✓Markdown gives way to Markup after a 26% slide in 5 weeks
2026-09-04Read Markdown55.36+2.2% to today Markup gives way to Markdown after a 22% rise in 9 weeks
2026-07-02Read Markup45.38+24.7% to today ✓First review on file: Markup
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Lamb Weston Holdings, Inc. holds its Markup at $56.60. Consolidating, no directional conviction, held for 165 days.
As held on the ledger · 2026-11-04
Phase
Markup
Quantitative state
Consolidating, no directional conviction, held for 165 days
Price at the screen
$56.60
Valuation
30.93 trailing · 16.03 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.47
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
53.43%
Below 33%
Interest-bearing debt is 53.4% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
11.48%
Below 49%
Money owed to the company is 11.5% of assets, under the 49% limit.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Lamb Weston Holdings,'s business is in a permissible area, but its interest-bearing debt is about 53% of the company, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when LW's ethical verdict changes
Today LW does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Undervalued vs our fair value, as of 4 Nov 2026: it trades at roughly an 11% discount to our $63.32 fair value, 0.70% revenue growth.
Fair value range in USD, drawn from the 2026-11-04 screen. The gold marker is the market price at the same screen. A 10.6% discount to the base estimate.
Where our models see it going: fair-value estimate $63.32, with a range of $52.98 to $88.29, dated to the 2026-11-04 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Frozen potato maker fails to clear our bar
Every time a fast food chain in Ohio or a supermarket in Germany restocks the freezer aisle, Lamb Weston is somewhere in the supply chain. Yet the business grows revenue at just 3 percent a year with only a 5 percent profit margin and an unknown competitive moat. At 15.5 times forward earnings the shares sit near the median analyst target of 46 dollars, offering no real margin of safety once you strip away the modest 14 percent gap to our own fair value.
We pass. The ethical screen is clean, return on equity reaches 17 percent and the sector is defensive, but none of that overcomes the lack of growth or pricing power that would justify a higher multiple or a larger position. Opportunity rating sits at none for a reason.
Commodity crop costs and shifting restaurant demand remain live risks even in packaged foods. The stock is not expensive, yet it is not interesting either. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
LW trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-01Markup$54.08+0.6%Entry 11
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 0.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are down 18%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (12 analysts) rates it buy, with a mean price target of $46.
2026-10-25Markup$53.78+3.5%Entry 10
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 3.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are down 18%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (12 analysts) rates it buy, with a mean price target of $46. Since the last review it its composite score eased.
2026-10-18Markup$51.96+26.2%Entry 9
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 26.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 18%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (12 analysts) rates it buy, with a mean price target of $46.
2026-10-11Markup · changed$41.18+0.0%Entry 8
The framework has shifted from markdown to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 18%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (12 analysts) rates it buy, with a mean price target of $46.
2026-10-02Markdown$41.18-12.9%Entry 7
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 12.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 18%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (12 analysts) rates it buy, with a mean price target of $46. It reported earnings in this window, a natural checkpoint for the thesis.
2026-09-24Markdown$47.29-14.6%Entry 6
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 14.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 18%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (12 analysts) rates it buy, with a mean price target of $46. It reported earnings in this window, a natural checkpoint for the thesis.
2026-09-04Markdown · changed$55.36+5.3%Entry 5
The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 5.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 18%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (12 analysts) rates it buy, with a mean price target of $46.
2026-08-04Markup$52.55+15.8%Entry 4
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 15.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 18%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (12 analysts) rates it buy, with a mean price target of $46.
2026-07-18Markup$45.38+0.0%Entry 3
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 18%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (12 analysts) rates it buy, with a mean price target of $46.
2026-07-03Markup$45.38+0.0%Entry 2
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
